Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Chooses Genedata Expressionist for Oncology Research
Leading clinical-research institute of the Robert Bosch Stiftung (Stuttgart, Germany) uses Genedata Expressionist for managing, processing, and interpreting clinical NGS data
January 22, 2014
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) has selected Genedata Expressionist® as the bioinformatics platform for pharmacogenomics- and oncology-related translational research. IKP, one of the premier clinical research facilities in Germany, focuses on improved patient care through personalized medicine. Developing biomarkers that predict drug efficacy as well as drug toxicity, IKP research drives treatment decisions that bring the right drugs to the right patients.
Genedata Expressionist provides IKP with a comprehensive software platform to process, interpret, and manage terabytes of transcriptomics, genomics, epigenomics, and clinical data from next-generation sequencing (NGS), microarrays, and qPCR experiments. IKP collaborates with Genedata to further develop and customize Genedata Expressionist to meet specific requirements of organizing and integrating omics data from numerous clinical studies. The collaboration will further focus on the development of analytical workflows that identify driver mutations associated with poor drug response or prognosis.
“With the number of clinical studies employing next-generation technologies rapidly increasing and advancing, we face the challenge of organizing, integrating, and interpreting massive amounts of genomic data combined with a large variety of clinical information,” said Prof. Dr. med. Matthias Schwab, head of IKP Stuttgart. “Genedata Expressionist provides a comprehensive platform that allows us to efficiently extract the most relevant scientific and clinical insights from our experiments. It is particularly important for us that Genedata Expressionist covers all aspects of NGS data management and analysis, from raw data to results.”
Taking NGS Experiments from Research to Clinical Applications
Genedata Expressionist is an oncology-focused enterprise-level software solution. Its data integration capabilities allow researchers to enrich their experiments with genomics data from a wide range of public data repositories.
Used by several leading pharmaceutical companies, Genedata Expressionist helps researchers find new drug targets, develop biomarkers for drug response and drug toxicity, and identify new indications or combination therapies for existing drugs. It is an integral tool for interdisciplinary oncology teams requiring audit and reporting facilities and enables oncologists to easily share, store, and publish results while ensuring data integrity.
“We are excited about our collaboration with the IKP, a global leader in developing advanced personalized medicine approaches for better patient care,” noted Dr. Othmar Pfannes, CEO of Genedata. “We are committed to investing in personalized medicine applications and partnerships that help us to continuously innovate data processing and ultimately make Genedata Expressionist the system of choice for translation research in oncology.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.